MLD's Plasmalogen Drug PPI-1040 for RCDP receives FDA Orphan Drug Designation (ODD) Shawn RitchieSeptember 5, 2019
MLD granted second Pre-IND meeting with the FDA for PPI-1040 and treatment of RCDP Shawn RitchieJanuary 4, 2019
Abstract detailing plasmalogen replacement therapy accepted for presentation in Torino, Italy, in March 2018. Shawn RitchieJanuary 4, 2018
